Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:2472-2479, 2005
© 2005 by the American Diabetes Association, Inc.

Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes
Original Article

Lipid, Lipoproteins, C-Reactive Protein, and Hemostatic Factors at Baseline in the Diabetes Prevention Program

the Diabetes Prevention Program Research Group*

Address correspondence and reprint requests to Diabetes Prevention Program Coordinating Center, The Biostatistics Center, George Washington University, 6110 Executive Blvd., Suite 750, Rockville, MD 20852. E-mail: dppmail{at}biostat.bsc.gwu.edu


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
OBJECTIVE—Individuals with impaired glucose tolerance (IGT) appear to be at increased risk for cardiovascular disease (CVD) due at least in part to an increased prevalence of risk factors. We evaluated lipid, lipoprotein, C-reactive protein (CRP), fibrinogen, and tissue plasminogen activator (tPA) levels at study entry in the largest multiethnic cohort of participants with IGT described, namely in the Diabetes Prevention Program (DPP).

RESEARCH DESIGN AND METHODS—Measurements were performed at the baseline visit of 3,819 randomized participants of the DPP. Among 3,622 participants who were not taking lipid-lowering medicines, cardiovascular risk factors were analyzed in relation to demographic, anthropometric, and metabolic measures. Major determinants of risk factors were assessed in multivariate analysis.

RESULTS—Over 40% of participants had elevated triglyceride, LDL cholesterol, and CRP levels and reduced HDL cholesterol levels. Men had higher triglyceride and tPA and lower HDL cholesterol concentrations and smaller LDL particle size than women, whereas women had higher CRP and fibrinogen levels. African Americans had less dyslipidemia but higher fibrinogen levels, and Asian Americans had lower CRP and fibrinogen levels than Caucasians and Hispanics. The surrogate measure of insulin resistance (homeostasis model assessment of insulin resistance [HOMA-IR]) had the strongest association with HDL cholesterol, triglyceride, and tPA levels and LDL particle size. BMI had the greatest influence on CRP and fibrinogen levels. Using median splits of indexes of insulin resistance and insulin secretion (insulin-to-glucose ratio), participants with greater insulin resistance had a more adverse CVD risk-factor profile, whereas insulin secretion had little influence on risk factors.

CONCLUSIONS—The pattern of CVD risk factors in participants with IGT in the DPP exhibits substantial heterogeneity and is significantly influenced by race, sex, and age, as well as by obesity, glucose, and insulin measures. The degree of insulin resistance, as reflected by HOMA-IR, showed the greatest association with the cardiovascular risk factors.

Abbreviations: CRP, C-reactive protein • CVD, cardiovascular disease • DPP, Diabetes Prevention Program • HOMA-IR, homeostasis model assessment of insulin resistance • IGR, insulin-to-glucose ratio • IGT, impaired glucose tolerance • tPA, tissue plasminogen activator • WHR, waist-to-hip ratio


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in type 2 diabetes, with a rate 2–4 times that in the general population (1). The basis for this increased risk has been attributed to a cluster of cardiovascular risk factors including hyperglycemia, hypertension, dyslipidemia, abdominal obesity, insulin resistance, and altered hemostasis (2). Prospective follow-up of individuals with normal or impaired glucose tolerance (IGT) has demonstrated that those destined to progress to diabetes already have an increased frequency of several of these risk factors (3), indicating that the mechanisms responsible for the increased prevalence of CVD in diabetes may be operating before the development of frank hyperglycemia.

IGT constitutes a clinically identifiable state that has been associated with an increased prevalence of cardiovascular risk factors such as hypertension and dyslipidemia (4,5) as well as elevated markers of impaired fibrinolysis (6) and C-reactive protein (CRP) (7), a novel predictor of cardiovascular events (8), and of progression to diabetes in pre-diabetic individuals (9). However, it is still controversial as to whether or to what extent IGT is associated with an increased risk of CVD (10). Most of the available reports have involved relatively small groups of individuals, in whom age, sex, ethnicity, and pathophysiologic variability (11) could significantly contribute to the heterogeneity of the study populations. In this report, we have examined lipid and lipoprotein levels, hemostatic and inflammatory markers, and their relationships to demographic, anthropometric, and biochemical variables present at baseline in the largest cohort of participants recruited with IGT, namely those who participated in the Diabetes Prevention Program (DPP). A separate analysis describing the prevalence of hypertension and its relations with body weight and insulin in this cohort has previously been published (12).


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
RESULTS
 CONCLUSIONS
 References
 
Full details of the DPP protocol have been published (13). The current report includes 3,819 participants in all four treatment arms seen at baseline. Individuals were recruited from a variety of sources based on the perceived risk for development of diabetes. Written informed consent was obtained from all participants before screening, consistent with the Helsinki Declaration and the guidelines of each center’s institutional review board. The initial screening step consisted of a fasting glucose measurement and, if eligible, was followed by a 75-g oral glucose tolerance test. Inclusion criteria included a fasting plasma glucose value of 5.3–6.9 mmol/l (≤6.9 mmol/l for American Indians) and a 2-h plasma glucose of 7.8–11.1 mmol/l following the glucose load, aged ≥25 years, and BMI ≥24 kg/m2 (≥22 kg/m2 for Asian Americans because of differences in body size in this population). Major exclusions included a recent myocardial infarction, symptoms of coronary heart disease, major illness, prior diagnosis of diabetes, or use of medications known to impair glucose tolerance, as previously detailed (14). Participants with >6.77 mmol/l triglyceride were also excluded. Standardized interviewer-administered questionnaires were used to obtain self-reported data on personal medical history. Self-reported race/ethnicity was classified according to the question employed in the 1990 U.S. Census questionnaire (15). Of 3,819 randomized participants, 197 (5.2%) were receiving lipid-lowering medications and were excluded from this analysis. Overall adiposity was assessed by BMI. Waist circumference was assessed in the standing position midway between the highest point of the iliac crest and the lowest point of the costal margin in the mid-axillary line. Hip circumference was assessed at the level of the femoral greater trochanter. All anthropometric measures reflected the average of two measurements.

All the analytical measurements were performed at the central biochemistry laboratory (Northwest Lipid Research Laboratories, University of Washington, Seattle, WA). Plasma glucose was measured by the glucokinase method. HbA1c (A1C) was measured by ion-exchange chromatography (Variant; BioRad). Insulin measurements were performed by a polyethylene glycol–accelerated double antibody radioimmunoassay method. The homeostasis model assessment for insulin resistance (HOMA-IR) was calculated as follows (16):

. The ratio of the change in insulin-to-glucose concentrations between 0 and 30 min after oral glucose (incremental insulin-to-glucose ratio [IGR]) was calculated as an index of insulin secretory capacity (17). Measurements of total cholesterol and triglycerides were enzymatically performed using methods standardized to the Centers for Disease Control and Prevention Reference Methods (18). HDL fractions for cholesterol analysis were obtained by the treatment of whole plasma with dextran sulfate Mg2+ (19). LDL cholesterol was calculated by the Friedewald equation (20). In participants with triglycerides >4.5 mmol/l, the lipoprotein fractions were separated using preparative ultracentrifugation of plasma by ß quantification (21). LDL flotation distribution was determined by a single-density gradient ultracentrifugation procedure, as previously described (22). LDL buoyancy (Rf) is calculated as the LDL peak fraction divided by the total number of fractions collected. This technique uses an Rf cut point to discriminate between LDL phenotypes A (>0.263) and B (≤0.263). CRP and fibrinogen levels in plasma were immunochemically measured using the Behring Nephelometer autoanalyzer. Tissue plasminogen activator (tPA) levels were measured in citrated plasma using an enzyme-linked immunosorbent assay (Asserachrom tPA; Diagnostica Stago), which measures total tPA antigen.

Statistical analysis
Baseline characteristics were described using means, SD, and 95% confidence limits for quantitative variables and the numbers and corresponding percentages for categorical variables. Comparisons among groups were made using ANOVA for quantitative variables and the {chi}2 test of independence for categorical variables. The nominal P values are listed with no adjustment for multiple comparisons. To assess the association of various factors with each risk factor, multiple regression models were fit in stages. This avoids the bias in the estimates of coefficients and tests of significance introduced by stepwise model building. Variables were entered into the model in blocks to allow identification of mediating interrelationships between covariates in the model as follows: demographics (age, female sex, ethnicity), adiposity (BMI, waist-to-hip ratio [WHR]), insulinemia (fasting insulin, HOMA-IR), and glycemia (fasting glucose, A1C). Transformations of independent (x) and dependent (y) variables were used when appropriate.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
CONCLUSIONS
 References
 
The mean age of the population was 50.3 years, two-thirds were female, and the mean BMI was 32.0 kg/m2 for men and 35.0 kg/m2 for women. Caucasians comprised the major ethnic group (55%), followed by African Americans (20%), Hispanics (16%), American Indians (5%), and Asians (4%). Mean fasting and postchallenge glucose were 5.9 and 9.1 mmol/l, respectively, and there was evident fasting hyperinsulinemia (13).

Lipids and lipoproteins
Table 1 shows lipids and lipoprotein cholesterol by ethnic group and sex. Since men and women had differences in their lipid profile, lipids and lipoprotein cholesterol were separately summarized. Women had a more favorable lipid profile than men, with significantly lower levels of triglyceride (1.70 vs. 1.95 mmol/l), VLDL (0.89 vs. 0.80 mmol/l), and LDL cholesterol (3.20 vs. 3.28 mmol/l) and significantly higher levels of HDL cholesterol (1.24 vs. 1.04 mmol/l) and LDL particle size (Rf of 0.270 vs. 0.257). Overall, triglyceride and VLDL cholesterol concentrations were lower and LDL particle size larger in African Americans compared with other ethnic groups, while HDL cholesterol levels were higher in African Americans for both sexes than in the other ethnic groups. Total cholesterol and LDL cholesterol values were significantly lower in American Indians than in other ethnic groups among women (P < 0.001).


View this table:
[in this window]
[in a new window]
  		Table 1— Lipids/lipoproteins, hemostatic variables, and CRP by sex and race

 
Figure 1 characterizes the adverse CVD profile by sex. Forty-nine and 29% of the men and 41 and 21% of women had triglyceride values ≥1.69 and ≥2.26 mmol/l, respectively. The prevalence of hypertriglyceridemia was lowest among African Americans (14% of men and 6% of women had triglyceride levels ≥2.26 mmol/l). LDL cholesterol concentrations ≥3.36 mmol/l were present in 41% of women and in 45% of men, respectively, varying only slightly between ethnic subgroups except for American-Indian women (23%) and African-American men (57%). Low HDL cholesterol concentrations (<1.03 mmol/l) were present in 52% of men, and, using the higher cutoff of <1.29 mmol/l for women, low HDL cholesterol values were present in 60% of women. Overall, 57% of the DPP cohort had low HDL cholesterol values by these criteria, and 31% (35% of men and 30% of women) had both low HDL cholesterol and triglyceride levels ≥1.69 mmol/l. The prevalence of this dyslipidemic combination did not vary much by ethnic group, except for African-American men (18%) and women (13%). Using an Rf cut point of ≤0.263 to define LDL phenotype B, 41% of men and 25% of women had small, dense LDL, respectively. These frequencies were lower among African-American men (29%) and women (15%) and were higher in American-Indian men (53%).



View larger version (20K):
[in this window]
[in a new window]
  		Figure 1— Prevalence of abnormal lipid, lipoprotein, and high-risk CRP levels by sex. Triglyceride and LDL cholesterol levels are expressed in mmol/l. Low HDL cholesterol is defined as <1.03 mmol/l for men and <1.29 mmol/l for women. Small, dense LDL is defined by LDL particle size ≤0.263 Rf. High-risk CRP is defined as CRP >3 mg/l.

 
Since 793 women in the study were receiving postmenopausal estrogen therapy (32%), a comparison was made between women receiving estrogens and those who were not. Estrogen users had higher triglyceride (mean 1.85 [95% CI 1.78–1.92] vs. 1.63 [1.59–1.67]; P < 0.001), total cholesterol (5.45 [5.39–5.52] vs. 5.17 [5.12–5.21]; P < 0.001), VLDL cholesterol (0.89 [0.86–0.93] vs. 0.76 [0.74–0.78]; P < 0.001), and HDL cholesterol (1.35 [1.33–1.38] vs. 1.19 [1.18–1.20]; P < 0.001) levels than nonestrogen users; despite this, nonestrogen users had higher HDL cholesterol levels than men (1.04 [1.02–1.05]; P < 0.001). Values for LDL cholesterol (3.20 [3.14–3.26] vs. 3.20 [3.16–3.24]) and mean LDL particle size (0.268 [0.266–0.271] vs. 0.270 [0.269–0.272]) were similar in estrogen compared with nonestrogen users.

CRP, fibrinogen, and tPA
The geometric mean (95% CI) CRP level was 3.50 mg/l (3.38–3.62) and was significantly higher in women than in men (4.64 vs. 1.92 mg/l). Asian Americans had significantly lower CRP values overall (1.86 mg/l) and in women (2.90 mg/l) compared with other ethnic groups. The mean ± SD fibrinogen concentration was 11.3 ± 2.5 µmol/l (383 ± 86 mg/dl) overall and was higher in women (11.7 µmol/l or 396 mg/dl) than in men (10.4 µmol or 354 mg/dl), lowest in Asian Americans (10.5 µmol/l or 358 mg/dl), and highest among African Americans (11.8 µmol/l or 402 mg/dl) and American Indians (11.8 µmol/l or 404 mg/dl). The mean tPA value overall was 11.3 ± 4.2 ng/dl, was significantly higher in men than in women (12.5 vs. 10.8 ng/dl), and differed among ethnic groups. CRP values were significantly higher in estrogen users than female nonusers (mean 5.42 mg/l [95% CI 5.08–5.78] vs. 4.30 [4.10–4.52]; P < 0.0001); whereas tPA levels (10.4 ng/dl [10.1–10.7] vs. 11.0 [10.8–11.2]; P < 0.001) and fibrinogen concentrations (11.5 µmol/l [11.3–11.6] vs. 11.7 [11.6–11.9]; P = 0.05) were significantly lower among those receiving estrogen treatment.

Multiple regression analysis
The relative effects of demographic, body fat, insulin resistance, and glycemia measures on lipids, lipoproteins, and inflammatory variables were assessed using multiple regression analysis, and covariates with significance levels of P < 0.001 are shown in Table 2. These four groups of factors explained 4.8% of the variation of LDL cholesterol. For HDL cholesterol, the group of factors explained 25.4% of the variation, with 4.1% of the variation attributable to being a woman and 3.4% to HOMA-IR. Being African American (versus Caucasian), as well as having higher levels of HOMA-IR, were associated with lower triglyceride values. The four factors explained 11.9% of the variation in LDL size, with HOMA-IR (3.1%) being the most significant. Sex and BMI were the most important determinants of the variation in both CRP and fibrinogen levels, with no influence of WHR; A1C had a small impact of 2.2% on fibrinogen values. The total effect of these determinants explained 29.3 and 19.0% of the variation in CRP and fibrinogen concentrations, respectively. Finally, HOMA-IR had the strongest association with tPA (R2 = 1.9%), while BMI and sex contributed approximately equally to its variation, with the combination of all four factors explaining 15.2% of the variation.


View this table:
[in this window]
[in a new window]
  		Table 2— Effect of demographics, adiposity, insulin resistance, and glycemia on lipids, lipoproteins, inflammatory, and hemostatic variables

 
Analysis by median splits of the IGR and HOMA-IR
Since HOMA-IR was a significant determinant of triglyceride, HDL cholesterol, LDL particle size, and tPA, and correlated significantly in univariate analysis with CRP and fibrinogen (data not shown), a comparison between those in the upper half of the HOMA-IR distribution was compared with those in the lower half. In addition, to explore whether ß-cell deficiency modulated the effects of HOMA-IR on risk-factor levels, the comparison was extended to include four groups based on median splits of both HOMA-IR and the IGR (Table 3). Triglyceride, VLDL cholesterol, CRP, fibrinogen, and tPA were all significantly higher and HDL cholesterol and LDL size significantly lower in the high–HOMA-IR than the low–HOMA-IR groups. There were no differences in any of the values between the high- versus low-IGR groups within either the low–or particularly in the high–HOMA-IR categories.


View this table:
[in this window]
[in a new window]
  		Table 3— Risk-factor levels by median splits of IGR and HOMA-IR

 

   CONCLUSIONS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
References
 
These results demonstrate that significant heterogeneity exists within the DPP IGT population, and this heterogeneity is likely to influence the risk for future CVD. Demographic factors had significant influences on the lipoprotein profile. Men had higher triglyceride and lower HDL cholesterol concentrations and smaller LDL particle size than women, as in the general population and in those with diabetes (23,24). Among women, postmenopausal estrogen users had higher triglyceride and total and HDL cholesterol values compared with women not receiving estrogen treatment. Of interest was the fact that LDL cholesterol levels were not reduced compared with nonusers, as has been reported in some studies (25). In this respect, the results are similar to those in the cohort with diabetes from the National Health and Nutrition Examination Survey III (26), suggesting heterogeneity in the LDL cholesterol response to hormone replacement therapy. Despite the differences between sexes, approximately one-third of both men and women had triglyceride values of ≥1.69 mmol/l together with reduced HDL cholesterol levels, which comprise two of three factors required to diagnose the metabolic syndrome (27). A similar proportion had the small dense LDL size phenotype. Almost 30% of men and 21% of women had frankly elevated triglyceride levels (≥2.26 mmol/l). Approximately 25% of the DPP population may therefore be eligible for treatment approaches aimed at lowering non-HDL cholesterol values, as proposed for participants with triglyceride levels ≥2.26 mmol/l by the National Cholesterol Education Program (27).

As has also been documented for diabetic and normoglycemic populations, African-American men and women had lower triglyceride and higher HDL cholesterol levels than did other ethnic groups (28,29). While this may be expected to have an impact on heart disease risk, evidence suggests that the incidence of CVD is not decreased in African Americans with glucose intolerance (30,31). Increasing age was associated with an elevation in total, LDL, and HDL cholesterol levels, as has been reported for the general population (32), but not with triglyceride or the total-to-HDL or LDL-to-HDL cholesterol ratios. Age-related increases in LDL cholesterol in participants with IGT will likely be accompanied by an increasing need for lowering of LDL cholesterol in older participants with IGT. Overall, 14% of the DPP population had LDL cholesterol values that merited drug therapy according to National Cholesterol Education Program criteria irrespective of other risk factors (>4.9 mmol/l), while another 40% with LDL cholesterol values >3.36 mmol/l would be eligible for drug therapy if they had two major risk factors. These findings indicate that a significant proportion of the subjects in DPP with IGT had lipid abnormalities associated with increased risk for CVD.

Among the metabolic factors examined, obesity, especially abdominal adiposity, is known to influence lipids and lipoproteins (33) and also contributes to the deterioration of the lipid profile with development of IGT (34). However, in the regression analysis, anthropometric variables were found to only modestly contribute to the lipid or lipoprotein measures. These results do not necessarily contradict the importance of the effect of increasing body weight or abdominal obesity on the lipid profile but rather that within the DPP cohort of overweight and obese participants, the effect of increasing body weight and WHR on the profile was limited. The severity of obesity and the lack of difference in BMI between Hispanic and non-Hispanic participants may also have explained the absence of triglyceride and HDL cholesterol differences between these two ethnic groups, as has been previously described (35). There was also little impact of glycemic measures on lipids and lipoproteins, probably for the same reason. Stronger associations were demonstrated between HOMA-IR and HDL cholesterol, triglyceride levels, and LDL particle size, as has been typical of previous studies in normoglycemic (36) as well as glucose-intolerant (37) populations, pointing to the importance of insulin resistance in the genesis of dyslipidemia in IGT. The significance of this result is strengthened by the finding that participants with HOMA-IR values in the upper half of the distribution had a significantly more adverse lipid profile than those in the lower half, and this did not appear to be influenced by whether they were in the higher or lower half of the range of an index of insulin secretion (IGR).

Recent evidence has implicated CRP levels as a predictor of cardiovascular events independent of other risk factors (8). However, the question as to whether this applies equally to obese, insulin-resistant, and glucose-intolerant populations is confounded by observations demonstrating strong associations between CRP levels and measures of obesity and insulin resistance (38,39). CRP was strongly influenced by BMI (but not independently by WHR) in this cohort, whereas measures of insulin resistance and the narrow range of glycemia in DPP had no independent effect. Furthermore, we found mean CRP levels to be lowest among the Asian-American subgroup, which had the lowest mean BMI among ethnic groups. In addition to body weight, female sex had a powerful effect on CRP levels, which were twice as high in women compared with men, as reported in the general population (40). High-risk CRP levels (>3 mg/l) were present in 57% of the DPP cohort and were far more prevalent in women (69%) than in men (32%). A significant portion of this sex difference appears to be related to body weight as well, since women were significantly more overweight than men in the DPP. In addition, 32% of women in the DPP were receiving estrogen treatment, and this was associated with increased CRP values, as has previously been reported (41). The clinical significance of this is unknown. An important unanswered question is whether the body weight/CRP relationship has any bearing on the predictive value of CRP for cardiovascular events in overweight and obese participants.

Like CRP, fibrinogen levels were strongly influenced by BMI but less strongly by sex, as has been reported before (42). This association likely reflects the fact that fibrinogen is known to be an inflammatory reactant (43). However, fibrinogen was also increased in relation to glucose levels, as has been previously noted (44). These influences are important because of evidence that fibrinogen levels are independently predictive of CVD (45). Aside from a modest relationship between A1C and LDL cholesterol levels, HDL cholesterol and tPA were the only risk factors studied here that appeared to be associated with increasing glucose levels within the IGT range. Levels of total tPA in cohort studies have fairly consistently been demonstrated to predict cardiovascular events (46), since they estimate the level of antifibrinolytic activity in plasma predominantly reflecting the tPA in tPA–plasminogen activator inhibitor-1 complexes (47). These levels were independently related to both total and abdominal adiposity and to HOMA-IR in the multiple regression model. Each of these factors has been proposed to increase the level of plasminogen activator inhibitor-1, the major inhibitor of fibrinolysis (6,48). Overall, participants with HOMA-IR values in the upper half of the distribution had significantly higher values of these novel risk factors. Estrogen treatment, on the other hand, was associated with reduced fibrinogen and tPA levels, as has been previously described (49).

Collectively, this analysis indicates that in a large multiethnic cohort with IGT, dyslipidemia is common, and while the prevalence varies by sex and ethnicity, it is also significantly influenced by the degree of insulin resistance and less by the level of obesity, insulin secretory reserve, or glucose intolerance in the population. Women with IGT have higher CRP and fibrinogen levels but slightly lower tPA values than their male counterparts, with the degree of excess body fat and of glucose intolerance emerging as the most important metabolic determinants of these novel risk factors. In summary, these findings reveal that participants with IGT exhibit significant heterogeneity in the prevalence of lipid, hemostatic, and inflammatory cardiovascular risk factors. Whether those with a more adverse pattern of CVD risk factors are more likely to become diabetic or develop CVD remains to be examined.


   Acknowledgments
 
Funding was provided by the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Child Health and Human Development, and the National Institute on Aging; the Office of Research National Center on Minority Health and Health Disparities, Office of Women’s Health; the Indian Health Service; Centers for Disease Control and Prevention; the General Clinical Research Program, National Center for Research Resources; the American Diabetes Association; Bristol-Myers Squibb; Lipha Pharmaceuticals; and Parke-Davis.

LifeScan, Health-O-Meter, Hoechst Marion Roussel, Merck-Medco Managed Care, Merck and Company, Nike Sports Marketing, Slim Fast Foods, and Quaker Oats donated materials, equipment, or medicines for concomitant conditions. McKesson BioServices, Matthews Media Group, and the Henry M. Jackson Foundation provided support services under subcontract with the coordinating center.

We thank the thousands of volunteers in this program for their devotion to the goal of diabetes prevention. This article was prepared by Ronald B. Goldberg (chair), Marinella G. Temprosa, Steven M. Haffner, Trevor J. Orchard, Robert Ratner, John M. Lachin, and Santina M. Marcovina.


   Footnotes
 
* A complete list of members of the DPP Research Group appears in ref. 13, and the members of the writing group appear in the ACKNOWLEDGMENTS. Back

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

Received for publication March 11, 2005. Accepted for publication July 19, 2005.


   References
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 

  1. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035–2038,1979
  2. Goldberg RB: Cardiovascular disease in diabetic patients. Med Clin North Am 84:81–93, 2000[Medline]
  3. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson K: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263:2893–2898, 1990[Abstract]
  4. Laakso M, Barrett-Connor E: Asymptomatic hyperglycemia is associated with lipid and lipoprotein changes favoring atherosclerosis. Arteriosclerosis 9:665–672, 1989[Abstract/Free Full Text]
  5. Burchfiel CM, Hamman RF, Marshall JA, Baxter J, Kahn LB, Amirani JJ: Cardiovascular risk factors and impaired glucose tolerance: the San Luis Valley Diabetes Study. Am J Epidemiol 131:57–70, 1990[Abstract/Free Full Text]
  6. Festa A, D-Agostino R Jr, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, Haffner SM: Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. Arterioscler Thromb Vasc Biol 19:562–568, 1999[Abstract/Free Full Text]
  7. Festa A, D’Agostino R, Tracy RP, Haffner SM: C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects: the Insulin Resistance Atherosclerosis Study. Diabet Med 19:939–943, 2002[Medline]
  8. Ridker PM, Hennekens CH, Burring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843, 2000[Abstract/Free Full Text]
  9. Festa A, D’Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute-phase reactants and plasminogen activator inhibitor 1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131–1137, 2000
  10. Haffner SM: Impaired glucose tolerance: is it relevant for cardiovascular disease? Diabetologia 40(Suppl. 2):S138–S140, 1997
  11. Haffner SM, Mykkännen L, Festa A, Burke JP, Stern M: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101:975–980, 2000[Abstract/Free Full Text]
  12. Diabetes Prevention Program Research Group: Hypertension, insulin and proinsulin in participants with impaired glucose tolerance. Hypertension 40:679–686, 2002[Abstract/Free Full Text]
  13. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403, 2002[Abstract/Free Full Text]
  14. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623–634, 1999[Abstract]
  15. Bureau of the Census: Census of the Population, 1990. Washington, DC, U.S. Government Printing Office, 1990
  16. Matthews DP, Hosker JP, Rudenski AS, Naylor GA, Treacher DF, Turner RL: Homeostasis model assessment: insulin resistance and ß-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419, 1985[Medline]
  17. Phillips DI, Clark PM, Hales CN, Osmond C: Understanding oral glucose tolerance: comparison of glucose and insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and secretion. Diabet Med 11:286–292, 1994[Medline]
  18. Warnick GR: Enzymatic methods for quantitation of lipoprotein lipids. Methods Enzymol 129:101–103, 1986[Medline]
  19. Warnick GR, Benderson J, Albers JJ: Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 28:1279–1288, 1982
  20. Friedewald WT, Levy RI, Fredrickson DS: Estimation of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499–502, 1972[Abstract]
  21. Hainline A Jr, Karon J, Lippel K (Eds.): Manual of Laboratory Operations. 2nd ed. Lipid Research Clinics Program, Lipid and Lipoprotein Analysis, Washington, DC, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health (updated 1983)
  22. Hokanson JE, Austin MA, Brunzell JD: Measurement and clinical significance of low density lipoprotein subclasses. In Handbook of Lipoprotein Testing. Rifai N, Warnick GR, Dominiczak MH, Eds. Washington, DC, American Association for Clinical Chemistry Press, 1997, p. 267–282
  23. McNamara JR, Campos H, Ordivas JM, Peterson J, Wilson PWF, Schaefer EJ: Effect of gender, age and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 7:483–490, 1987[Abstract/Free Full Text]
  24. Haffner SM, Mykkanen L, Stern MP, Paidi M, Howard BV: Greater effect of diabetes on LDL size in women than in men. Diabetes Care 17:1164–1171, 1994[Abstract]
  25. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605–613, 1998[Abstract/Free Full Text]
  26. Crespo CJ, Smit E, Snelling A, Sempos CT, Andersen RE, NHANES III: Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: results from the third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 25:1675–1680, 2002[Abstract/Free Full Text]
  27. National Institutes of Health: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, MD, National Institutes of Health, 2001 (NIH publ. no. 01-3670)
  28. Cook CB, Erdman DM, Ryan GJ, Greenlund KJ, Giles WH, Gallina DL, El-Kebbi IM, Ziemer DC, Ernst KL, Dunbar VG, Phillips LS: The pattern of dyslipidemia among urban African-Americans with type 2 diabetes. Diabetes Care 23:319–324, 2000[Abstract]
  29. Cowie CC, Howard BV, Harris MI: Serum lipoproteins in African Americans and whites with non-insulin dependent diabetes in the US population. Circulation 90:1185–1193, 1994[Abstract/Free Full Text]
  30. Schmidt MI, Duncan BB, Watson RL, Sharett AR, Brancati FL, Heiss G: A metabolic syndrome in Whites and African-Americans: the Atherosclerosis Risk in Communities baseline study. Diabetes Care 19:414–418, 1996[Abstract]
  31. Keil JE, Sutherland SE, Knapp RG, Lackland DT, Gazes PC, Tyroler HA: Mortality rates and risk factors for coronary disease in black as compared with white men and women. N Engl J Med 329:73–78, 1993[Abstract/Free Full Text]
  32. The Lipid Research Clinics Program Epidemiology Committee: Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 60:427–439, 1979[Abstract/Free Full Text]
  33. Nieves DJ, Cnop M, Retzlaff B, Walden CE, Brunzell JD, Knopp RH, Kahn SE: The atherogenic profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes 52:172–179, 2003[Abstract/Free Full Text]
  34. Pascot A, Despres JP, Lemieux I, Bergeron J, Nadeau A, Prud’homme D, Tremblay A, Lemieux S: Contribution of visceral obesity to the deterioration of the metabolic profile in men with impaired glucose tolerance. Diabetologia 43:1126–1135, 2000[Medline]
  35. Mitchell BD, Stern MP, Haffner SM, Hazuda HP, Patterson JK: Risk factors for cardiovascular mortality in Mexican Americans and non-Hispanic whites: San Antonio Heart Study. Am J Epidemiol 131:423–433, 1990[Abstract/Free Full Text]
  36. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1495–1507, 1988
  37. Haffner SM, D’Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF: Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22:562–568, 1999[Abstract]
  38. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131–1415, 1999[Abstract/Free Full Text]
  39. Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy R, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47, 2000[Abstract/Free Full Text]
  40. Wong ND, Pio J, Valnecia R, Thakal G: Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III. Prev Cardiol 4:109–114, 2001[Medline]
  41. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE: Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100:713–716, 1999[Abstract/Free Full Text]
  42. Krobot K, Hense HW, Cremer P, Eberele E, Keil U: Determinants of plasma fibrinogen: relationship to body weight, waist-to-hip ratio, smoking, alcohol, age and sex. Results from the second MONICA Augsburg survey 1989–1990. Arterioscler Thromb12:780–788, 1992
  43. Yudkin JS, Kumari M, Humphries SE, Mohammed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214, 2000[Medline]
  44. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D’Agostino RB, Wilson PWF: Hyperinsulinemia, hyperglycemia and impaired hemostasis: the Framingham Offspring Study. JAMA 283:221–228, 2000[Abstract/Free Full Text]
  45. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB: Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 258:1183–1186,1987
  46. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341:1165–1168, 1993[Medline]
  47. Chandler WL, Trimble SL, Loo SC, Mornin D: Effect of PAI-1 levels on the molar concentrations of active tissue plasmingen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 76:930–937, 1990[Abstract/Free Full Text]
  48. Vague P, Juhan-Vague I, Chabert V, Alessi C: Fat distribution and plasminogen activator inhibitor activity in non-diabetic women. Metabolism 35:250–253, 1989
  49. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H: Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85:619–625, 2001[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Evid Based Complement Alternat MedHome page
K. Yang
A Review of Yoga Programs for Four Leading Risk Factors of Chronic Diseases
Evid. Based Complement. Altern. Med., December 1, 2007; 4(4): 487 - 491.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum